НовостиBenzingaRocket One's Hoth Therapeutics Subsidiary Plans To End Its Phase 2a Clinical Study Of HT-001 After Interim Efficacy Data; Intends To Seek FDA Feedback For Conducting HT-001 Into Potential Phase 3 Clinical Program Rocket One's Hoth Therapeutics Subsidiary Plans To End Its Phase 2a Clinical Study Of HT-001 After Interim Efficacy Data; Intends To Seek FDA Feedback For Conducting HT-001 Into Potential Phase 3 Clinical Program Benzinga 2026.11.03 13:20 (GMT+0) Открыть на Benzinga Другие новости